U.S. markets close in 4 hours 4 minutes

Eiger BioPharmaceuticals, Inc. (EIGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.08-0.22 (-2.14%)
As of 11:53AM EDT. Market open.

Eiger BioPharmaceuticals, Inc.

2155 Park Boulevard
Palo Alto, CA 94306
United States
650 272 6138
http://www.eigerbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Mr. David A. Cory R.Ph, MBABus. Founder, Pres, CEO & Director862.03kN/A1964
Dr. Jeffrey S. GlennFounder, Scientific Advisor & Independent Director53.5kN/A1963
Mr. Sriram Ryali M.B.A.Chief Financial Officer461.98kN/A1981
Dr. Stephana E. PattonGen. Counsel, Corp. Sec. & Chief Compliance Officer417.8kN/A1971
Mr. Eldon C. Mayer III, M.B.A.Exec. VP & Chief Commercial Officer55.5kN/A1961
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.

Corporate Governance

Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.